We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double‐blinded, placebo‐controlled trial.
- Authors
Sivalingam, Suvanjaa; Hein Zobel, Emilie; Hansen, Christian S.; Ripa, Rasmus S.; von Scholten, Bernt J.; Rotbain Curovic, Viktor; Kjaer, Andreas; Jensen, Jacob K.; Hansen, Tine W.; Rossing, Peter
- Abstract
The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial The difference in 30/15 ratio was, however, driven by a decrease in the placebo group with no change in the liraglutide group, and E/I ratio increased in both groups, merely more so in the liraglutide group. Cardiovascular autonomic neuropathy (CAN) is a frequent complication in diabetes associated with increased cardiovascular mortality.1 CAN is defined as impairment of the cardiovascular autonomic system. We used change of 30/15, E/I and Valsalva ratio within each treatment group and a mean delta SD between treatment groups of 0.28, 0.13 and 0.16, respectively, and calculated that 56, 75 and 19 participants in each treatment group, respectively, would be required.
- Subjects
TYPE 2 diabetes; LIRAGLUTIDE; SECONDARY analysis; CORONARY artery calcification; GLUCAGON-like peptide 1; RESPIRATION
- Publication
Diabetes, Obesity & Metabolism, 2022, Vol 24, Issue 8, p1638
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.14717